{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:39Z","timestamp":1792239099245,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01474-2","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:43:44Z","timestamp":1775303024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dynamics of BCMA expression in patients with relapsed\/refractory multiple myeloma receiving BCMA-directed CAR-T therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma Shifa","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-9079","authenticated-orcid":false,"given":"Alexandria","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Hovanky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Velayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S.","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Iberri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-1018","authenticated-orcid":false,"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"1474_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","volume":"65","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. Leuk Lymphoma. 2024;65:287\u2013300.","journal-title":"Leuk Lymphoma"},{"key":"1474_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"1474_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1474_CR4","unstructured":"FDA\u2019s recent approval of 2 CAR T-cell therapies a \u2018Big Step Toward\u2019 long-term control of myeloma for more patients | Leukemia and Lymphoma Society [Internet]. 2025 [cited 2025 Feb 20]. Available from: https:\/\/www.lls.org\/news\/fdas-recent-approval-2-car-t-cell-therapies-big-step-toward-long-term-control-myeloma-more."},{"key":"1474_CR5","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/j.jtct.2024.04.002","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis J, Ahmed N, Sannareddy A, Shaikh H, Shune L, et al. Outcomes of BCMA directed chimeric antigen receptor T-Cell (CART) therapy and teclistamab in patients with relapse-refractory multiple myeloma with extramedullary disease: a real-world experience of the US Myeloma Innovations Research Collaborative (USMIRC). Transplant Cell Ther. 2024;30:S384\u20135.","journal-title":"Transplant Cell Ther"},{"key":"1474_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2022017848","volume":"141","author":"O Van Oekelen","year":"2023","unstructured":"Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141:756\u201365.","journal-title":"Blood"},{"key":"1474_CR7","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u22655-Year) remission and survival after treatment with Ciltacabtagene Autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;JCO2500760."},{"key":"1474_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.2023023557","volume":"144","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024;144:402\u20137.","journal-title":"Blood"},{"key":"1474_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, Rasche L, Kort\u00fcm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023;108:958\u201368.","journal-title":"Haematologica"},{"key":"1474_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu YM, Mishler J, Hall S, Mannan R, Wang L, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022;13:3750.","journal-title":"Nat Commun"},{"key":"1474_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al. \u03b3-secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:7333.","journal-title":"Nat Commun"},{"key":"1474_CR12","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8:3562\u201375.","journal-title":"Blood Adv"},{"key":"1474_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"1474_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T cell activity. Cancer Discov. 2020;10:702\u201323.","journal-title":"Cancer Discov"},{"key":"1474_CR15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419\u201331.","journal-title":"Nat Med"},{"key":"1474_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20\u20138.","journal-title":"Nat Med"},{"key":"1474_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"1474_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022;40:53\u201369.e9.","journal-title":"Cancer Cell"},{"key":"1474_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet. 2024;404:353\u201363.","journal-title":"Lancet"},{"key":"1474_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMc2308544","volume":"389","author":"X Mi","year":"2023","unstructured":"Mi X, Penson A, Abdel-Wahab O, Mailankody S. Genetic basis of relapse after GPRC5D-targeted CAR T cells. N Engl J Med. 2023;389:1435\u20137.","journal-title":"N Engl J Med"},{"key":"1474_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","volume":"17","author":"D Zhou","year":"2024","unstructured":"Zhou D, Wang Y, Chen C, Li Z, Xu K, Zhao K. Targeting GPRC5D for multiple myeloma therapy. J Hematol Oncol. 2024;17:88.","journal-title":"J Hematol Oncol"},{"key":"1474_CR22","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"1474_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138:1081\u20135.","journal-title":"Blood"},{"key":"1474_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1474_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"1474_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616\u20139.","journal-title":"Nat Med"},{"key":"1474_CR27","unstructured":"International Myeloma Foundation [Internet]. [cited 20 Feb 2025]. International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. Available from: https:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple."},{"key":"1474_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1474_CR29","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129:2210\u201321.","journal-title":"J Clin Investig"},{"key":"1474_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","volume":"71","author":"DA Salem","year":"2018","unstructured":"Salem DA, Maric I, Yuan CM, Liewehr DJ, Venzon DJ, Kochenderfer J, et al. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma. Leuk Res. 2018;71:106\u201311.","journal-title":"Leuk Res"},{"key":"1474_CR31","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1182\/blood-2023-178954","volume":"142","author":"K Perica","year":"2023","unstructured":"Perica K, Nataraj S, Sjojstrand ML, Nagel K, Pavkovic E, Payson E, et al. Low target antigen expression mediates resistance to BCMA CAR T cell therapy. Blood. 2023;142:2124.","journal-title":"Blood"},{"key":"1474_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10591-1","volume":"23","author":"Y Xu","year":"2023","unstructured":"Xu Y, Mao X, Que Y, Xu M, Li C, Almeida VDF, et al. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma. BMC Cancer. 2023;23:123.","journal-title":"BMC Cancer"},{"key":"1474_CR33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate-mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174:911\u201322.","journal-title":"Br J Haematol"},{"key":"1474_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/cyto.b.22099","volume":"102","author":"H Sriram","year":"2022","unstructured":"Sriram H, Kunjachan F, Khanka T, Gawai S, Ghogale S, Deshpande N, et al. Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. Cytomet B Clin Cytom. 2022;102:462\u201370.","journal-title":"Cytomet B Clin Cytom"},{"key":"1474_CR35","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"1474_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:141.","journal-title":"J Hematol Oncol"},{"key":"1474_CR37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Am Soc Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Am Soc Clin Oncol"},{"key":"1474_CR38","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy BB2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"1474_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"1474_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"1451","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;1451:85\u201397.","journal-title":"Blood"},{"key":"1474_CR41","doi-asserted-by":"crossref","unstructured":"Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, et al. Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma: a CIBMTR analysis. Blood. 2025;blood.2024026216.","DOI":"10.1182\/blood.2024026216"},{"key":"1474_CR42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144:2375\u201388.","journal-title":"Blood"},{"key":"1474_CR43","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293\u2013300.","journal-title":"Nature"},{"key":"1474_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13\u201329.","journal-title":"Blood"},{"key":"1474_CR45","doi-asserted-by":"crossref","unstructured":"Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021;5:3794\u20138.","DOI":"10.1182\/bloodadvances.2021004418"},{"key":"1474_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56486-6","volume":"16","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Carleton M, Tanaka K, Sworder B, Syal S, Sahaf B, et al. Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma. Nat Commun. 2025;16:1824.","journal-title":"Nat Commun"},{"key":"1474_CR47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2024-201288","volume":"144","author":"F Maura","year":"2024","unstructured":"Maura F, Freeman CL, Lee H, Maclachlan KH, Durante M, Ziccheddu B, et al. Genomic determinants of resistance to anti-BCMA chimeric antigen receptor T-Cell (CART) therapies in patients with relapsed\/refractory multiple myeloma. Blood. 2024;144:247.","journal-title":"Blood"},{"key":"1474_CR48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1:146\u201354.","journal-title":"Blood Cancer Discov"},{"key":"1474_CR49","doi-asserted-by":"crossref","unstructured":"Jiang H. A prospective investigator-initiated phase 1\/2 study of BCMA\/CD19 dual-targeting CAR T therapy in patients with relapsed\/refractory multiple myeloma including those with extramedullary disease. In ASH; 2024 [cited 6 Mar 2025]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper201160.html.","DOI":"10.1182\/blood-2024-201160"},{"key":"1474_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","volume":"1","author":"S Simon","year":"2020","unstructured":"Simon S, Riddell SR. Dual targeting with CAR T cells to limit antigen escape in multiple myeloma. Blood Cancer Discov. 2020;1:130\u20133.","journal-title":"Blood Cancer Discov"},{"key":"1474_CR51","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","volume":"43","author":"NWCJ van de Donk","year":"2025","unstructured":"van de Donk NWCJ, Vega G, Perrot A, Anguille S, Oriol A, Minnema M, et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results. J Clin Oncol. 2025;43:7505\u20137505.","journal-title":"J Clin Oncol"},{"key":"1474_CR52","unstructured":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. A phase 1, open-label, dose-finding study of BMS-986453, dual targeting BCMAxGPRC5D chimeric antigen receptor T cells, in participants with relapsed and\/or refractory multiple myeloma [Internet]. clinicaltrials.gov; 2025 [cited 17 Jun 2025]. Report No.: NCT06153251. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06153251."},{"key":"1474_CR53","unstructured":"EHA 2025: Phase 2 study of Talquetamab + Teclistamab in patients with relapsed\/refractory multiple myeloma and extramedullary disease: redirectt-1 [Internet]. [cited 17 Jun 2025]. Available from: https:\/\/clin.larvol.com\/abstract-detail\/EHA%202025\/76411926."},{"key":"1474_CR54","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood-2019-129582","volume":"134","author":"DJ Green","year":"2019","unstructured":"Green DJ, Pont M, Cowan AJ, Cole GO, Sather BD, Nagengast AM, et al. Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase. Blood. 2019;134:1856.","journal-title":"Blood"},{"key":"1474_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen H, Yu T, Lin L, Xing L, Cho SF, Wen K, et al. \u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12:1\u201310.","journal-title":"Blood Cancer J"},{"key":"1474_CR56","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, et al. \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24:811\u201322.","journal-title":"Lancet Oncol"},{"key":"1474_CR57","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134:1585\u201397.","journal-title":"Blood"},{"key":"1474_CR58","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2022.281339","volume":"108","author":"E Garc\u00eda-Guerrero","year":"2023","unstructured":"Garc\u00eda-Guerrero E, Rodr\u00edguez-Lobato LG, Sierro-Mart\u00ednez B, Danhof S, Bates S, Frenz S, et al. All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica. 2023;108:568\u201380.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01474-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:02:26Z","timestamp":1779213746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01474-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS reports Research Funding: BMS, Janssen, Novartis, AbbVie. Consultancy\/Advisory board: BMS, Janssen, Sanofi, Takeda, Regeneron, AbbVie, Pfizer, BiolineRx, Legend, Kite, Arcellx, Genentech, Roche. CLM is a founder, Board Member, equity holder and consultant for Link Cell Therapies, has received consulting fees from CARGO, Ensoma, AstraZeneca, Immatics, RedTree Venture Capital, Grace Science, GBM NewCo, and Nektar, and research funding from Tune Therapeutics. YN: Advisory board Roche and Leica Biosystems; grant funding Roche & Kite Pharma. SD: Research funding from Kite, a Gilead Company and Kyverna Therapeutics. Consulting\/advisory role for Adaptive Biotechnologies, Incyte, and Bristol Myers Squibb, Kite Gilead, Johnson and Johnson. DBM reports consulting\/advisory roles for Adaptive Biotechnologies, Adicet, AlloGene, Janssen, Juno-Celgene-BMS, Kite-Gilead, Miltenyi Biotech, Novartis, Pharmacyclics LLC, an AbbVie Company, Precision Bioscience, and Takeda; and reports research funding from 2seventy bio, Adaptive Biotechnologies, Adicet Bio, AlloGene, Pharmacyclics LLC, an AbbVie Company, Genentech, Kite-Gilead, Miltenyi Biotech, Novartis, and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with all relevant institutional guidelines and regulations. The study protocol was approved by the Stanford University Institutional Review Board (IRB-43375; approved September 2025). All participants provided written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APROVAL AND CONSENT TO PARTICIPATE"}}],"article-number":"79"}}